Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-15
2003-04-15
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S341000, C514S357000, C546S272400, C546S272700, C546S258000, C546S300000
Reexamination Certificate
active
06548519
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to pyridoxine and pyridoxal analogue compounds, pharmaceutical compositions containing the pyridoxine and pyridoxal analogue compounds, and methods of treatment using a therapeutically effective amount of the pyridoxine and pyridoxal analogue compounds. The pyridoxine or pyridoxal analogues can be used in the treatment of undesired platelet aggregation, cardiovascular or related diseases, and symptoms thereof.
BACKGROUND OF THE INVENTION
Pyridoxal-5′-phosphate (PLP), an end product of vitamin B
6
metabolism, plays a vital role in mammalian health. Vitamin B
6
typically refers to pyridoxine, which is chemically known as 2-methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine and is represented by formula I:
Yet two additional compounds, pyridoxal of formula II
and pyridoxamine of formula III
are also referred to as vitamin B
6
. All three compounds serve as precursors to pyridoxal-5′-phosphate (PLP), which is chemically known as 3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridine-carboxaldehyde and is represented by formula IV:
PLP is the biologically active form of vitamin B
6
inside cells and in blood plasma. Mammals cannot synthesize PLP de novo and must rely on dietary sources of the precursors pyridoxine, pyridoxal, and pyridoxamine, which are metabolized to PLP. For instance, mammals produce PLP by phosphorylating pyridoxine by action of pyridoxal kinase and then oxidizing the phosphorylated product.
PLP is a regulator of biological processes and a cofactor in more than one hundred enzymatic reactions. It has been shown to be an antagonist of a purinergic receptor, thereby affecting ATP binding; it has been implicated in modulation of platelet aggregation; it is an inhibitor of certain phosphatase enzymes; and it has been implicated in the control of gene transcription. In previous patents (U.S. Pat. No. 6,051,587 and U.S. Pat. No. 6,043,259) the role of pyridoxal-5′-phosphate, and its precursors pyridoxal and pyridoxine (vitamin B
6
), in mediating cardiovascular health and in treating cardiovascular related diseases is disclosed. PLP is also a coenzyme in certain enzyme-catalyzed processes, for example, in glycogenolysis at the glycogen phosphorylase level, in the malate asparatate shuttle involving glycolysis and glycogenolysis at the transamination level, and in homocysteine metabolism.
There is a need to identify and administer drugs that can mimic one or more of the known biological actions of vitamin B-6 congeners but that are more potent than the vitamin B-6 congeners in their specific mode of action.
SUMMARY OF THE INVENTION
The present invention provides for pyridoxine and pyridoxal analogues, pharmaceutical compositions containing the pyridoxine and pyridoxal analogues, and methods for treatment based on administration of therapeutically effective amounts of the pyridoxine and pyridoxal analogues. Compounds and compositions of the invention can be used for the treatment of cardiovascular or related diseases and symptoms thereof.
The invention provides pyridoxine and pyridoxal analogues of Formula V:
or a pharmaceutically acceptable acid addition salt addition salt thereof, wherein:
R
5
is CH
2
OH or CHO;
R
1
is
n is an integer of 1 to 5;
R
2
, R
3
, and R
4
are each independently
hydrogen;
alkyl;
aryl or biaryl,
wherein the aryl or biaryl can be substituted with a cyano, alkyl, alkoxy, amino, hydroxy, halo, nitro, or alkanoyloxy;
amino;
acylamino;
anilino,
wherein the aniline ring can be substituted with a cyano, alkyl, alkoxy, amino, hydroxy, halo, nitro, or alkanoyloxy;
nitro; or
guanidino.
In another aspect, the invention is directed to a pharmaceutical composition that includes a pharmaceutically acceptable carrier in combination with a therapeutically effective amount of a compound of Formula V or a pharmaceutically acceptable acid addition salt of a compound of Formula V.
In another aspect, the invention is directed to a method of treating cardiovascular or related diseases and symptoms thereof. The method includes administering to a mammal a therapeutically effective amount of a compound of Formula V or a pharmaceutically acceptable acid addition salt of a compound of Formula V in a unit dose form. The method can further include concurrent administration of another therapeutic agent.
In another aspect, the invention is directed to a method of reducing platelet aggregation and the symptoms there of a mammalian patient. The method includes administering to the mammalian patient a therapeutically effective amount of a compound of Formula V. In some instances the patient may suffer from heparin-induced thrombocytopenia (HIT).
In another aspect, the invention is directed to a method of reducing or preventing heparin-induced thrombus formation in a mammalian patient suffering from HIT. The method includes administering to the mammalian patient a therapeutically effective amount of a compound of Formula V.
In another aspect, the invention is directed to a method or reducing brain damage in a mammalian patient following embolic or hemorrhagic stroke. The method includes administering to the mammalian patient a therapeutically effective amount of a compound of Formula V.
REFERENCES:
patent: 3206463 (1965-09-01), Baetz
patent: 3910921 (1975-10-01), Esanu
patent: 3987177 (1976-10-01), Giudicelli et al.
patent: 4032534 (1977-06-01), Chodkiewicz
patent: 4036844 (1977-07-01), Thorne et al.
patent: 4053607 (1977-10-01), Thorne et al.
patent: 4137316 (1979-01-01), Esanu
patent: 4167562 (1979-09-01), Evers
patent: 4361570 (1982-11-01), Fici
patent: 4369172 (1983-01-01), Schor et al.
patent: 4374841 (1983-02-01), Descamps et al.
patent: 4515771 (1985-05-01), Fine
patent: 4567179 (1986-01-01), Lombardino
patent: 4569938 (1986-02-01), Esanu
patent: 4569939 (1986-02-01), Esanu
patent: 4581363 (1986-04-01), Esanu
patent: 4605741 (1986-08-01), Zagnoli et al.
patent: 4696920 (1987-09-01), Bentzen et al.
patent: 4730042 (1988-03-01), Hege et al.
patent: 4735950 (1988-04-01), Esanu
patent: 4735956 (1988-04-01), Baldwin et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4843071 (1989-06-01), Hohenwarter
patent: 4962121 (1990-10-01), Hamberger et al.
patent: 5001115 (1991-03-01), Sloan
patent: 5053396 (1991-10-01), Blass
patent: 5118505 (1992-06-01), Kóltringer
patent: 5130324 (1992-07-01), Ulrich et al.
patent: 5132115 (1992-07-01), Wolter et al.
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5213813 (1993-05-01), Kornecki et al.
patent: 5254557 (1993-10-01), Buckle et al.
patent: 5254572 (1993-10-01), Serfontein
patent: 5272165 (1993-12-01), Ulrich et al.
patent: 5278154 (1994-01-01), Lacoste et al.
patent: 5288716 (1994-02-01), Speck
patent: 5326757 (1994-07-01), Demopoulos
patent: 5328453 (1994-07-01), Sibalis
patent: 5372999 (1994-12-01), Schneider et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5441972 (1995-08-01), Ogata et al.
patent: 5504090 (1996-04-01), Neely
patent: 5563126 (1996-10-01), Allen et al.
patent: 5569459 (1996-10-01), Shlyankevich
patent: 5569648 (1996-10-01), Lewis et al.
patent: 5631271 (1997-05-01), Serfontein
patent: 5633228 (1997-05-01), Lewis et al.
patent: 5648335 (1997-07-01), Lewis et al.
patent: 5728684 (1998-03-01), Cheng et al.
patent: 5733884 (1998-03-01), Barbul et al.
patent: 5733916 (1998-03-01), Neely
patent: 5770215 (1998-06-01), Moshyedi
patent: 5795873 (1998-08-01), Allen
patent: 5804163 (1998-09-01), Gibby et al.
patent: 5804594 (1998-09-01), Murad
patent: 5833998 (1998-11-01), Biedermann et al.
patent: 5834446 (1998-11-01), Dow et al.
patent: 5840685 (1998-11-01), Fujii et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 5858017 (1999-01-01), Demopulos et al.
patent: 5859051 (1999-01-01), Adams et al.
patent: 5874420 (1999-02-01), Pelleg
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5888514 (1999-03-01), Weisman
patent: 5944020 (1999-08-01), Markov et al.
patent: 6043259 (2000-03-01), Dhalla et al.
patent: 831350 (1976-01-01), None
patent: 863754 (1978-05-01),
Davis Zinna Northington
Medicure International Inc.
Merchant & Gould P.C.
LandOfFree
Pyridoxine and pyridoxal analogues: novel uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridoxine and pyridoxal analogues: novel uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridoxine and pyridoxal analogues: novel uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3091219